GB1096951A - Vaccines comprising inactivated myxoviruses - Google Patents

Vaccines comprising inactivated myxoviruses

Info

Publication number
GB1096951A
GB1096951A GB11807/64A GB1180764A GB1096951A GB 1096951 A GB1096951 A GB 1096951A GB 11807/64 A GB11807/64 A GB 11807/64A GB 1180764 A GB1180764 A GB 1180764A GB 1096951 A GB1096951 A GB 1096951A
Authority
GB
United Kingdom
Prior art keywords
virus
inactivated
vaccine
ccl2
myxoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB11807/64A
Other languages
English (en)
Inventor
Alexander David Kanarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE661402D priority Critical patent/BE661402A/xx
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GB11807/64A priority patent/GB1096951A/en
Priority to FR1587316D priority patent/FR1587316A/fr
Priority to IL23187A priority patent/IL23187A/en
Priority to DK143165AA priority patent/DK111007B/da
Priority to CH393965A priority patent/CH471896A/de
Priority to NL656503607A priority patent/NL149377B/xx
Publication of GB1096951A publication Critical patent/GB1096951A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/20—Rubella virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation
    • C12N2760/18463—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C12N2760/18863—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB11807/64A 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses Expired GB1096951A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BE661402D BE661402A (enrdf_load_stackoverflow) 1964-03-20
GB11807/64A GB1096951A (en) 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses
FR1587316D FR1587316A (enrdf_load_stackoverflow) 1964-03-20 1965-03-19
IL23187A IL23187A (en) 1964-03-20 1965-03-19 Production of vaccines
DK143165AA DK111007B (da) 1964-03-20 1965-03-19 Fremgangsmåde til inaktivering af myxovirus.
CH393965A CH471896A (de) 1964-03-20 1965-03-22 Verfahren zur Inaktivierung von Myxoviren
NL656503607A NL149377B (nl) 1964-03-20 1965-03-22 Werkwijze om een geinactiveerd myxovirus te bereiden.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB11807/64A GB1096951A (en) 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses

Publications (1)

Publication Number Publication Date
GB1096951A true GB1096951A (en) 1967-12-29

Family

ID=9993058

Family Applications (1)

Application Number Title Priority Date Filing Date
GB11807/64A Expired GB1096951A (en) 1964-03-20 1964-03-20 Vaccines comprising inactivated myxoviruses

Country Status (7)

Country Link
BE (1) BE661402A (enrdf_load_stackoverflow)
CH (1) CH471896A (enrdf_load_stackoverflow)
DK (1) DK111007B (enrdf_load_stackoverflow)
FR (1) FR1587316A (enrdf_load_stackoverflow)
GB (1) GB1096951A (enrdf_load_stackoverflow)
IL (1) IL23187A (enrdf_load_stackoverflow)
NL (1) NL149377B (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292197A (en) * 1969-05-16 1972-10-11 American Home Prod Method for the disruption of viruses
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
FR2483779A1 (fr) 1980-06-05 1981-12-11 Synthelabo Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles

Also Published As

Publication number Publication date
FR1587316A (enrdf_load_stackoverflow) 1970-03-20
BE661402A (enrdf_load_stackoverflow)
DK111007B (da) 1968-04-29
NL6503607A (enrdf_load_stackoverflow) 1965-09-21
CH471896A (de) 1969-04-30
NL149377B (nl) 1976-05-17
IL23187A (en) 1969-01-29

Similar Documents

Publication Publication Date Title
JP2749887B2 (ja) 連続細胞系におけるｉｂｄｖの産生
US3755557A (en) Spray vaccines
US4188375A (en) Process for the preparation of vaccines
US3699222A (en) Production of viral interfering substances
Bagust Comparison of the biological, biophysical and antigenic properties of four strains of infectious bovine rhinotracheitis herpesvirus
GB1096951A (en) Vaccines comprising inactivated myxoviruses
Bachmayer et al. Preparation and properties of a novel influenza subunit vaccine
Beard et al. Preparation of Newcastle disease virus hemagglutination-inhibition test antigen
Salk Partial Purification of the Virus of Epidemic Influenza by Adsorption on Calcium Phosphate.
KR101617464B1 (ko) Ｉｐｖ―ｄｐｔ 백신
Kono et al. An epidemic of Getah virus infection among racehorses: properties of the virus
Nerome et al. Absence of neuraminidase from influenza C virus
McKee et al. Reactivation of overneutralized mixtures of influenza virus and antibody
Hoyle et al. Further studies of complement-fixation in influenza: Antigen production in egg-membrane culture and the occurrence of a zone phenomenon
CA1152895A (en) Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them
Laver et al. Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine
CS223975B2 (en) Method of making the virus vaccines of the spring-summer meningoencephtalitide
WO2001009290A2 (es) Serotipo de virus de bronquitis infecciosa aviar
DE69116155T2 (de) Neuramidase und glulaktoseoxidase als vaccinadjuvans
DE2528584A1 (de) Verfahren zur inaktivierung der virusinfektiositaet unter gleichzeitiger stabilisierung von virusantigenen
GB1140316A (en) Influenza virus sub-unit vaccine
CA1214724A (en) Vaccine for bluetongue disease employing platinum compounds
Parker Inactivation of African horse-sickness virus by betapropiolactone and by pH
Buckley et al. Production of hemagglutinin by dengue virus in HeLa cells
RU2181295C1 (ru) Вирионная цитомегаловирусная вакцина и способ ее получения